Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)

Purpose: Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy. Such tests seem especially interesting in “intermediate” clinico-pathological risk categories. The psychological impact of the decision uncertainty in these...

Full description

Bibliographic Details
Main Authors: Frédérique Penault-Llorca, Fabrice Kwiatkowski, Antoine Arnaud, Christelle Levy, Marianne Leheurteur, Lionel Uwer, Olfa Derbel, Annick Le Rol, Jean-Philippe Jacquin, Christelle Jouannaud, Nathalie Quenel-Tueux, Véronique Girre, Cyril Foa, Emmanuel Guardiola, Alain Lortholary, Stéphanie Catala, Séverine Guiu, Alexander Valent, Diane Boinon, Jérome Lemonnier, Suzette Delaloge
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Breast
Subjects:
Breast cancer
Genomic test
Chemotherapy
Patient reported outcomes
EndoPredict®
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977619305843

Internet

http://www.sciencedirect.com/science/article/pii/S0960977619305843

Similar Items